Key Takeaways
- RBC Capital upgraded Astera Labs (ALAB) price target to $250 from $225, maintaining Outperform
- The boost reflects anticipated Scorpio-X switch revenue linked to Trainium3, expected to begin Q3 2026
- RBC forecasts Scorpio switch revenue climbing from $130M in 2025 to $390M in 2026
- UBS launched coverage with a Neutral stance and $180 target, pointing to intensifying switching competition
- ALAB delivered Q4 2025 EPS of $0.58, surpassing the $0.51 estimate, with revenue climbing 92% year-over-year to $270.6M
Astera Labs received attention from Wall Street on Monday as two separate analyst firms weighed in with contrasting perspectives on the semiconductor company’s prospects.
Astera Labs, Inc. Common Stock, ALAB
RBC Capital elevated its price objective for Astera Labs to $250 from the previous $225, while maintaining its Outperform designation. Shares were changing hands near $175.80 during the session, representing approximately a 10% daily gain.
The optimistic outlook from RBC hinges on Scorpio-X, Astera’s upcoming switch solution. The investment firm anticipates that Trainium3-associated Scorpio-X revenue streams will materialize starting in the third quarter of 2026, creating additional revenue opportunities per accelerator unit.
RBC’s financial models indicate total Scorpio switch revenue will surge from $130 million in 2025 to $390 million in 2026 — effectively tripling within twelve months.
The upgraded $250 price objective represents 74 times RBC’s calendar year 2027 earnings per share forecast of $3.37. The previous target employed a 67x multiple. RBC cited several new product launches, an expansive total addressable market, anticipated revenue expansion of 40–50%, and gross profit margins exceeding 70% as justification for the elevated valuation multiple.
Astera’s current gross margin stands at 75.69%, accompanied by revenue expansion of 115% over the trailing twelve-month period.
UBS Adopts More Conservative Stance
UBS also launched coverage of ALAB on Monday, settling on a Neutral rating with a $180 price objective — marginally above the stock’s trading level at the time.
Analyst Natalia Winkler recognized the company has established a legitimate presence in AI networking infrastructure over a five-year period, demonstrating solid execution with retimers and cultivating relationships beyond its primary customer, AWS. Astera introduced its retimer solutions in 2019 and has subsequently expanded adoption among additional hyperscale providers.
UBS anticipates 2027 revenues landing 4% above Wall Street consensus, propelled by retimers and the PCIe/UA Link switching product lineup. However, for 2028, UBS projects results 3% beneath consensus, highlighting increasing competitive pressures in the switching segment as a concern.
Valuation represents the primary reservation for UBS. Astera commands a high-40s 2027 price-to-earnings ratio, substantially elevated compared to AI networking competitors. The firm indicated it identifies superior risk-reward opportunities within alternative networking investments.
Recent Quarterly Performance Supports Optimistic Thesis
Supporting both analytical perspectives is a robust recent financial performance. Astera disclosed Q4 2025 earnings per share of $0.58, exceeding the $0.51 Wall Street consensus by nearly 14%.
Quarterly revenue totaled $270.6 million, representing 92% year-over-year growth.
A dozen analysts have adjusted earnings projections upward for forthcoming periods, based on InvestingPro intelligence.
The stock has delivered 223% returns over the past year. Notwithstanding that impressive performance, ALAB’s PEG ratio of 0.47 indicates the valuation may appear more reasonable than the headline price-to-earnings multiple of 143 suggests — particularly when adjusting for growth prospects.
RBC’s $250 price objective implies approximately 42% potential appreciation from prevailing levels. UBS’s $180 target provides minimal upside opportunity from current valuations.
